Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage SCLC (RATIONALE-312): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial.
Ying ChengYun FanYanqiu ZhaoDingzhi HuangXingya LiPeng ZhangMafei KangNong YangDiansheng ZhongZhen WangYan YuYu ZhangJun ZhaoTai QinChenqi ChenShiangjiin LeawWenjuan ZhengYong Songnull nullPublished in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer (2024)
Tislelizumab plus chemotherapy exhibited statistically significant clinical benefit and manageable safety compared with placebo plus chemotherapy as first-line treatment in patients with advanced ES-SCLC.